Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
30.99
-1.65 (-5.06%)
At close: Apr 7, 2026, 4:00 PM EDT
31.70
+0.71 (2.29%)
Pre-market: Apr 8, 2026, 7:36 AM EDT
Axogen Employees
Axogen had 622 employees as of December 31, 2025. The number of employees increased by 170 or 37.61% compared to the previous year.
Employees
622
Change (1Y)
170
Growth (1Y)
37.61%
Revenue / Employee
$362,071
Profits / Employee
-$25,246
Market Cap
1.61B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 622 | 170 | 37.61% | 622 | 0 |
| Dec 31, 2024 | 452 | 24 | 5.61% | 451 | 1 |
| Dec 31, 2023 | 428 | 32 | 8.08% | 426 | 2 |
| Dec 31, 2022 | 396 | -55 | -12.20% | 394 | 2 |
| Dec 31, 2021 | 451 | 83 | 22.55% | 428 | 23 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AdaptHealth | 10,900 |
| Enovis | 7,802 |
| UFP Technologies | 4,846 |
| Neogen | 2,974 |
| Tandem Diabetes Care | 2,500 |
| Artivion | 1,800 |
| Inspire Medical Systems | 1,333 |
| Establishment Labs Holdings | 1,004 |
AXGN News
- 7 weeks ago - Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 2 months ago - Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Axogen Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 - GlobeNewsWire
- 4 months ago - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) - GlobeNewsWire
- 4 months ago - FDA approves Axogen's nerve repair graft - Reuters
- 5 months ago - Axogen, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire